Suggested remit: To appraise the clinical and cost effectiveness of tocilizumab within its marketing authorisation for treating systemic sclerosis.
- Status:
- Awaiting development
- Technology type:
- Medicine
- Decision:
- None selected
- Process:
- STA Standard
- ID number:
- 1396
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 04 July 2018 (14:00) | Scoping workshop (Manchester) |
| 28 June 2018 | Note added to the project documents |
| 15 May 2018 - 13 June 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual